Skip to main content

Table 6 Survival analysis of risk scores model in HCC patients

From: Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma

Variables

Patients

NO.of event

MST

HR (95% CI)

P

Adjusted HR a (95% CI)

Adjusted P a

TCGA

n = 370

 

Days

    

 Low risk

185

55

2456

1

   

 High risk

185

75

1149

1.740 (1.227–2.468)

0.02

1.643 (1.124–2.402)

0.01

GSE14520

n = 212

 

Months

    

 Low risk

106

33

NA

1

 

1

 

 High risk

106

49

54.8

1.848 (1.187–2.876)

0.007

2.237 (1.424–3.514)

< 0.001

  1. MST, median survival time; HR, hazard ratio; CI, confidence interval
  2. aAdjusted for tumor size, cirrhosis, BCLC stage in GSE14520 cohort; and adjusted for tumor stage and radical resection in TCGA cohort
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us